DexCom Inc. (DXCM) News
Filter DXCM News Items
DXCM News Results
|Loading, please wait...|
DXCM News Highlights
- DXCM's 30 day story count now stands at 20.
- Over the past 8 days, the trend for DXCM's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- AJG, ALC and CAH are the most mentioned tickers in articles about DXCM.
Latest DXCM News From Around the Web
Below are the latest news stories about DEXCOM INC that investors may wish to consider to help them evaluate DXCM as an investment opportunity.
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
The first Moncler Lunettes collection produced with EssilorLuxottica (ESLOY) is called Fall-Winter 2024.
Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.
DexCom's (NASDAQ:DXCM) 29% CAGR outpaced the company's earnings growth over the same five-year period
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...
SAN DIEGO, November 21, 2023--DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29th.
If you're having trouble finding your portfolio's next growth holding, here are three great options to choose from -- or you can choose all three.
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
In this article, we will take a look at the 13 stocks that outperform the S&P 500 every year for the last 5 years. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Stocks That Outperform the S&P 500 Every Year for the Last 5 […]
Zacks.com featured highlights include DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services
DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services are part of the Zacks Screen of the Week article.
Novo Nordisk's (NYSE: NVO) Ozempic is indicated to treat diabetes, and its wild success and household name is making a few cardiometabolic device companies rather nervous. With a powerful tool to manage blood glucose levels in hand, patients may not have as much of a need for the glucose monitors and insulin pumps they formerly relied on, so the fearful argument goes.